During a Clinical Consult presentation, Atish D. Choudhury, MD, PhD, spoke with CancerNetwork? about long-term safety and efficacy data for agents related to metastatic castration-sensitive prostate cancer (mCSPC) as well as several unmet needs for this patient population. "We have been seeing an increase in men who are presenting initially with metastatic disease," explained Choudhury, co-director of the Prostate Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center and assistant professor of medicine at Harvard Medical School. "It means that more men are presenting in a space and we're getting some increasing data around how to optimally manage them." Choudhury expanded on those unmet needs for patients with mCSPC and the various treatment options that are considered for each individual patient.
展开▼
